In September, I discussed new anticoagulants Xarelto and Eliquis. My prior post concludes by noting patients deserve drugs approved only after careful study for safety.

Shortly after that post, the ISMP Quarterwatch also raised issues concerning the safety of new anticoagulants rivaroxaban (Xarelto), dabigatron (Pradaxa), and apixaban (Eliquis). According to Quarterwatch:

The adverse event reports for oral anticoagulants confirm the evidence that long-term use remains one of the highest-risk drug treatments in older patients, with injury rates of 15-20% per year. As previously noted in this publication, bringing a new generation of oral anticoagulants to market based on ease of use rather than improved safety was a major wrong turn. In addition, two of the three novel anticoagulants have pharmacological profiles that raise questions about their simple, unmonitored dosing regimens.

The use of these drugs raises troubling health questions. Risks of personal injury or death due to uncontrolled bleeding, hemorrhaging, and stroke are serious. Because of these risks, adequate safety studies and clinical trials should have been completed before patients were given these medications.